Our current development effort focuses on the innovative M102 program. M102 is a proprietary disease-modifying drug candidate based on recently understood disease pathways in neurogenerative disease. Neurodegenerative disease represents a range of medical conditions which primarily affect the neurons in the human brain. Neurons are the building blocks of the nervous system which includes the brain and spinal cord. Normally, neurons do not reproduce or replace themselves, so when they become damaged or dead, they cannot be replaced by the body. Neurodegeneration is the progressive loss of structure or function of neurons, including death of neurons. Many neurodegenerative diseases occur as a result of neurodegenerative processes. Such diseases are incurable, resulting in progressive degeneration and/or death of neuron cells. As research progresses, many similarities appear that relate these diseases to one another on a sub-cellular level. There are many parallels between different neurodegenerative disorders, including atypical protein assemblies and induced cell death. Neurodegeneration can be found in many different levels of neuronal circuitry, ranging from molecular to systemic. Examples of neurodegenerative diseases include Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis, Batten Disease, and Friedreich's Ataxia.